Conference abstracts
Abstracts
410 abstracts. Filter by title, author, or session.
Novel targets and treatments for stimulant use disorders and depression
Social-neurobehavioral phenotypes for advancement of social-target intervention in cocaine use disorder
Feasibility and preliminary efficacy of tirzepatide for individuals with moderate/severe methamphetamine use disorder
Accelerated course of intermittent theta burst for methamphetamine use disorder: Feasibility and EEG-derived functional connectivity correlates of treatment response
Integrating cognitive-behavioral therapy with repetitive transcranial magnetic stimulation (CBT/TMS): A novel combined neuromodulation-psychotherapy model for prenatal depression
Conducting clinical trials using combined treatment modalities: Challenges, opportunities, and insights for future regulatory consideration
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE study
Interim data from a randomized placebo-controlled trial of accelerated transcranial magnetic intermittent theta-burst stimulation and adjunctive d-cycloserine for suicidal ideation
Synergistic biobehavioral treatments to reduce depression and compulsivity
Novel therapeutics with entactogenic effects - a new frontier for mood and anxiety disorders?
EMP-01 (R-MDMA) as a next-generation entactogen: Mechanistic rationale and therapeutic potential in social anxiety disorder
Intravenous ketamine improves social anhedonia in patients with treatment-resistant depression and suicidal ideation
Ketamine’s potential for treating loneliness in treatment resistant bipolar depression
Objective measures of empathy: Prosocial learning and mood states
Targeted interventions for suicide prevention
Using intensive, real-time monitoring designs to identify proximal risk factors for suicidal ideation among adolescents
Changes in symptoms of suicidal ideation and related symptoms with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
Psychosocial interventions for older adults with depression and varying degrees of cognitive functioning after a suicide-related hospitalization
Efficacy and safety of a single dose of psilocybin for chronic active suicidal ideation: Experiences in an open label trial
Improving metabolic health in mental illness: A transdiagnostic approach
Psymetric 2.0: Development, refinement and external validation of clinic-ready cardiometabolic prediction models for young people with psychosis spectrum disorders
Treating psychotropic associated weight gain in individuals with intellectual and developmental disability: A retrospective chart review study
PTSD and diabetes: A two-way street in metabolic and mental health
PMCID: PMC7170451.
Strategies to improve treatment effect detection in MDD trials
Strategies to improve treatment effect detection in MDD trials
Functional connectivity of the striatum as a biomarker of treatment response to KCNQ-targeted agents in depression
Depression and disturbances in circadian rhythms: Pathways for novel treatment development
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
The ASCP model psychopharmacology curriculum update
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
RE104. A novel serotonergic psychedelic 4-OH-DIPT prodrug for the treatment of postpartum depression
A new dawn for social anxiety treatment: Clinical advancement of the novel V1aR antagonist, NTX-1472
DT-101 – a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator demonstrates favorable tolerability and functional biomarkers in phase 1 healthy volunteer trial
Seltorexant, adjunctive to antidepressants, in adults with major depressive disorder with insomnia symptoms: Phase 3 studies
Ketamine treatment for non-motor symptoms of Parkinson's disease
Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder
Unlocking medicines for neuropsychiatry by enhancing oral absorption using a lymphatic-targeting prodrug technology
BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program
Novel oral rapid-acting neuroactive steroid for treatment of postpartum depression: A placebo-controlled phase 3 clinical trial of lpcn 1154a
A randomized, placebo-controlled trial of the fatty acid amide hydrolase inhibitor palmitoylethanolamide in bipolar depression
Prospective replication of an EEG biomarker for predicting changes in attention in ALTO-203, an H3 inverse agonist
Findings from the ASCP presidential task force on psychotropic drug polypharmacotherapy
Underutilized augmenters in polypharmacy regimens: The case for lithium
Rational and irrational psychopharmacology combinations
When to switch versus augment pharmacotherapies
Mondo combo: Do combinations of antipsychotics ever make any sense?
Comorbidity polypharmacy: Simultaneous vs. Successive introduction of co-pharmacotherapies
Safety, tolerability, and drug-drug interaction concerns in polypharmacology regimens
Waking up to excessive daytime sleepiness in psychiatry and how to make wearables work for measuring sleep and activity
Sleep assessments as predictors of health risk and depression
Smartwatch measurements and controlled depression: Comparative analyses on physical activity and sleep
PMCID: PMC9008579. sleep and its utility for mental health and well-being research: The case for longitudinal measurements
Deploying artificial intelligence (AI) and large language models (LLMs) in psychiatry drug development
Designing the next generation of studies of psychedelics for difficult to treat depression
Using neuroimaging to elucidate psychedelic mechanisms of action on brain circuits
Long term outcomes from psilocybin and response to re-dosing for difficult to treat depression
Critical methodological decisions in psychedelic drug trials
Regulatory plenary: AI-based tools in CNS drug development: A regulatory framework for clinical trial applications
ASCP lifetime awardee talk and Nasrallah awardee
The tyranny of the p-value: Effect size matters
A short journey through a 50 years of progress in the treatment of depression
Clinical updates on neurotherapeutics: Disease state
SGAs vs mood stabilizers: The paradigm shift in core treatment for bipolar disorder
An update on bipolar disorder: Evidence, challenges, and solutions
The pharmacologic treatment of schizophrenia: Status report
Exciting new findings from clinical trials in the treatment of post-traumatic stress disorder
Schizophrenia polygenic risk is negatively associated with body mass index in two population cohorts
Retrospective analysis of real-world transition strategies for xanomeline and trospium chloride in adult patients with schizophrenia
Sleep estimation from low-frequency smartphone sensors via Bayesian hidden Markov model
Neural and behavioral evidence from reinforcement learning converge in support of relaxed beliefs under LSD
Augmenting dorsolateral prefrontal cortex-targeted tDCS with cognitive reappraisal in cocaine use disorder
Mixed amphetamine salts and lisdexamfetamine as adjunctive treatment for bipolar depression: Pooled analysis of two randomized controlled trials
Brain-to-brain movie neurofeedback reduces craving in opioid use disorder
33959050; PMCID: PMC8093505.
Evaluating hepatic effects of serial ketamine infusions for treatment-resistant bipolar depression
Drug liking and craving of intravenous ketamine when prescribed for the treatment of mood disorders in a monitored setting: A descriptive analysis
Combined ketamine and cognitive behavioral therapy: Leveraging metaplasticity to enhance outcomes
Repeated ketamine infusions for treatment-resistant bipolar depression: A randomized, midazolam-controlled clinical trial
10.1177/20451253231202723. PMID: 37771417; PMCID: PMC10524067.
AMPA receptor binding potential is reduced in the anterior cingulate cortex of female patients with PTSD
PMID: 31959988.
Durability of TMS treatment for veterans with MDD examined via significant psychiatric events associated with relapse (SPEAR): A proposed new composite outcome measure for high severity/low frequency mental health events
Is brain insulin action implicated in the biology of depression? A pilot neuroimaging study in adolescents
Semaglutide improves health-related quality of life in major depressive disorder independent of mood change: Evidence for metabolic and motivational pathways
Moving beyond sleep: The broader connection between the orexin system and psychiatric disorders
Incorporating novel muscarinic agents for schizophrenia into clinical practice: Overcoming clinical inertia
6736(25)02365-7. PMID: 41763745
AI beyond evil robots: Ensuring transformative means better
Update from federal and other funding agencies
NIAAA update: Focus on the medications development program
Patient-centered comparative effectiveness research
Advancing therapeutics for substance use disorders through nida’s therapeutics development program
PMID: 40395395; PMCID: PMC12089859. update from defense health agency psychological health research portfolio
Updates from veteran health administration (VA) research initiatives
NIMH update
Durability outcomes in treatment resistant depression
Transcranial magnetic stimulation: Durability of anti-depressant response
Durability of vagus nerve stimulation treatment-resistant depression: New, more comprehensive findings from the recover trial
Beyond the acute course: Exploring the durability of ketamine's antidepressant effects in the maintenance phase of treatment
15. PMID: 40834563.
40319349; PMCID: PMC12143125. how durable are acute effects of psilocybin on treatment-resistant depression?
Evolving understandings of psychedelics in clinical research
Understanding psilocybin administration: Dose, participant characteristics, and therapeutic context
Recruiting, retaining, and tailoring psychedelic clinical trials for vulnerable populations
Evaluating the clinical utility of psilocybin therapy versus other psychedelic drug interventions for the treatment of posttraumatic stress disorder
Building collaborative capacity in early career psychopharmacology: Strategies for effective partnerships across academia, industry, and clinical practice
The evolving nature of academic-industry partnerships
PMCID: PMC11000613 take-aways from my experience starting out in clinical psychopharmacology research
10.1056/NEJM1994052633021131530 – 1533 why do we need team science approaches in neurobiological and clinical studies
39171416; PMCID: PMC11652247.
03008-5. PMID: 39054336; PMCID: PMC11272929. development of esketamine. An academic -industry dream collaboration
Are early career clinical researchers in psychiatry an endangered species?
The young investigator as a pluripotent stem cell: The role of industry-academic partnerships in a successful career
Communication and conflict management: Practical tools for effective leadership in research
Advances in depression research: A tribute to Nolan Williams
Understanding and harnessing the opioid effects of ketamine
Non-invasive amygdala neuromodulation in humans with focused ultrasound: Neurobiological and clinical effects in mood, anxiety, and trauma-related disorders
Clinical and neural outcomes of magnesium-ibogaine for traumatic brain injury in special operations forces veterans
Photobiomodulation with near infrared light: A novel treatment for psychiatric disorders
Dose-dependent effects of transcranial photobiomodulation on brain temperature in patients with major depressive disorder: A spectroscopy study
6. PMID: 39370461. Transcranial photobiomodulation for Alzheimer's disease
Transcranial infrared laser stimulation improves cognitive performance and induces a biphasic cerebral perfusion response in remitted bipolar disorder
Uncovering mechanisms of photobiomodulation behind clinical changes: Evidence from neuroimaging
Lessons from transforming the psychiatric healthcare system: How to improve outcomes?
Alignment for progress: A movement to bring change
One expert by experience journey
Challenges of building a learning health system for early psychosis care
Transforming the healthcare system with the bipolar action network
Developing treatments for the non-motor symptoms of Parkinson's disease
AB-300, a novel 5-HT2A/2C agonist, reverses motivational deficits in a tetrabenazine model of Parkinson’s disease apathy
Psilocybin therapy for depression in Parkinson’s disease
Targeting synaptic loss in Parkinson’s disease depression with ketamine
Artificial intelligence: Understanding the present and anticipating the future
Using artificial intelligence and social media data for population mental health surveillance
Assessing AI for clinical care and research
Bridging AI innovation and clinical trial data in psychiatry: Mathematical limits and clinical consequences
What to know about ketamine safety: Patient monitoring, neurotoxicity, and considerations for special patient populations
Racemic ketamine side effects, adverse reactions, and monitoring
Ketamine for depression, but at what cost? Evidence for neurotoxicity from human and animal studies
Use of ketamine for depression in special populations
The discovery and clinical development of (2R,6R)- hydroxynorketamine for depression and pain
From ketamine metabolite to candidate therapeutic: Preclinical discovery of (2R,6R)-HNK relevance to depression treatment
Preclinical development of (2R,6R)-hydroxynorketamine for human clinical evaluation
Clinical development of (2R,6R)-hydroxynorketamine: Ongoing trials in TRD and OCD and phase 1 safety, tolerability, and PK/PD results in healthy volunteers
Evaluation of the (2R,6R)-hydroxynorketamine as a potential clinical useful analgesic agent: Translational experience from preclinical to human study
New and anticipated interventions for perinatal depression
Pathophysiological mechanisms of perinatal depression
Epigenetic biomarkers in postpartum depression and postpartum psychosis
Approved and potential treatments for PPD
Addiction and neuromodulation in pregnancy
The future DSM: Designing a scientific, inclusive, and practical diagnostic manual for modern psychiatry
The future DSM: Designing a scientific, inclusive, and practical diagnostic manual for modern psychiatry
Structure and dimensions subcommittee
The DSM subcommittee on candidate biomarkers and biological factors
Regulatory challenges: Ask the experts
W1. The phase 2/3 gain trial of the first-generation p. gingivalis gingipain inhibitor atuzaginstat in mild-to-moderate probable Alzheimer’s disease: New cerebrospinal fluid biomarker data
W2. Galantamine-memantine combination regulating the kynurenine pathway metabolism in the treatment of post-stroke depression and post-stroke cognitive impairments and prevention of stroke
W3. Dynamic causal modeling of triple-network connectivity varies by suicide attempt history
W4. A review of evidence and an algorithm for use of psychopharmacology in the treatment of tobacco use disorder in behavioral health settings
W5. Evidence from randomized controlled trials in substance use disorders with memantine, galantamine, n-acetylcysteine, and doxazosin/prazosin
W6. Changes in smoking-related outcomes with tirzepatide in individuals with methamphetamine use disorder who smoke
W7. Changes in depressive symptoms with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
W8. Safety and tolerability of 32-week-long treatment with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
W9. First dose treatment effects with injectable weekly and monthly buprenorphine (CAM2038) and the relationship between buprenorphine plasma concentrations and withdrawal suppression in participants with opioid use disorder
W10. A new dawn for social anxiety treatment: Clinical advancement of the novel V1aR antagonist, NTX-1472
W11. Treatment patterns among incident and persistent patients with generalized anxiety disorder (GAD)
W12. The impact of comorbid psychiatric disorders on misconducts among incarcerated individuals with attention-deficit/hyperactivity disorder: A preliminary study
W13. The neurochemical and anxiolytic-like effects of centanafadine in preclinical assays in the rat and mouse
W14. Growing trend of stimulant use in young patients misdiagnosed with ADHD: A case-based systematic review
W15. Emotional dysregulation symptom outcomes in adults with ADHD treated with centanafadine: A pooled post hoc analysis of two phase 3 trials
W16. The persistence of neuroepithelial progenitors in neocortical organoids: Impeding accurate models for drug screening in neurodevelopmental disorders
W17. Long-term safety and tolerability of cariprazine in pediatric patients with autism spectrum disorder, bipolar I disorder or schizophrenia: Final results from an open-label study
W18. E2086, a selective orexin receptor-2 agonist: Study for promoting wakefulness in patients with narcolepsy type 1
W19. The complex multi-system symptom inventory (COMSS): A new instrument to assess symptom frequency, impact, and postural dependence across multiple central and peripheral autonomic symptom domains
W20. Static and dynamic disruptions of salience-network flexibility in veterans with comorbid mild TBI and alcohol use disorder
W21. Successful early treatment of anti-n-methyl-d-aspartate receptor encephalitis associated with small cell lung cancer in an elderly male patient: A case report
W22. GH001 efficacy is independent of prior antidepressant treatment failures in treatment-resistant depression: A post hoc analysis of a phase 2b randomized controlled trial
W23. Examining the impact of patient-centered approaches on the assessment and management of cognitive impairment in major depressive disorder
W24. Seltorexant versus quetiapine extended release as adjunctive treatment in major depressive disorder with insomnia symptoms: Phase 3 trial
W25. Benefits of adjunctive vagus nerve stimulation in difficult-to-treat depression: Outcomes of a naturalistic European cohort (RESTORE-LIFE) compared to the USA recover randomized controlled trial
W26. Pooled individual patient data analysis of three phase 2 trials supports vasopressin V1b receptor antagonism (BH-200 250 mg BID) as an antidepressant mechanism for the treatment of major depressive disorder (MDD)
W27. Genetically defined subgroup analysis reveals differential response to vasopressin V1b antagonism in patients with MDD pre-exposed to antidepressant in the current episode: Post-hoc analysis of the phase 2 OLIVE trial
W28. Characteristics of depression episodes to inform real-world health states for major depressive disorder and treatment-resistant depression
W29. Longitudinal profiling of treatment trajectories in SSRI-anchored MDD using agentic AI
W30. Dimensions of psychedelic experience predicting antidepressant response to psilocybin across diagnoses
W31. Anxious depression as predictor of clinical outcomes in treatment-resistant depression (ASCERTAIN-TRD)
W32. Neuroactive steroid changes pre-and post-ketamine during a double-blind, crossover clinical trial: An exploratory study
W33. Association of major depressive disorder with insomnia symptoms with healthcare resource use and cardiovascular and metabolic conditions – analysis of national health and nutrition examination survey
W34. Esmethadone (REL-1017) in patients with antidepressant tachyphylaxis: A post hoc efficacy analysis in a pre-randomization–defined subgroup
W35. Preclinical behavioral and pharmacological characteristics of TN-001, a novel, non-hallucinogenic neuroplastogen for the treatment of major depressive disorder
W36. Metabolic profile of adjunctive lumateperone 42 mg in major depressive disorder: A pooled analysis of 2 randomized, placebo-controlled trials
W37. Lumateperone 42 mg in major depressive disorder: Demographic and clinical subgroups efficacy analysis in a phase 3 randomized placebo-controlled trial
W38. Efficacy of lumateperone 42 mg for the treatment of major depressive disorder: Analysis of demographic and clinical subgroups in a phase 3 randomized placebo-controlled trial
W39. Psychopharmacology of ENX-104: A potent dopamine (DA) D2/D3 receptor antagonist for the treatment of neuropsychiatric disorders associated with anhedonia
W40. Impact of GH001 on depressive symptoms, anxiety, and quality of life in treatment-resistant depression: Results from a phase 2b trial
W41. Rapid and sustained improvement in anhedonia following inhaled mebufotenin (GH001) treatment in patients with treatment-resistant depression
W42. Effects of dextromethorphan-bupropion (45mg/105mg) in participants with major depressive disorder and anxious distress
W43. HJ-006: A non-hallucinogenic synaptogenic compound with rapid and sustained antidepressant efficacy
W45. Psychomotor disturbance as a predictor of treatment response in mood disorders: A systematic review
W46. The monotherapy antidepressant pipeline problem: Only 8 approvals out of 28 attempts in the last 25 years
W47. Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy
W48. Early motivational and hedonic responses to antidepressants in major depressive disorder: A real-world evidence study
W49. Real-world evidence of the clinical and preference impact of a prescription digital therapeutic for major depressive disorder: An ongoing prospective study in an academic health system
W50. Anxiolytic effects of dextromethorphan-bupropion (45mg/105mg): Post hoc analyses across trials in major depressive disorder
W51. Multimodal identification of neurobiological subtypes associated with ketamine response in treatment-resistant depression using NETRAAI
W52. Orexin 2 receptor agonists as a potential therapeutic approach to the treatment of sleep-wake disturbance, fatigue, and cognitive deficit in neuropsychiatric disease
W53. A novel disease-modifying strategy for narcolepsy type 1 – preclinical rationale and development roadmap for the Doxa platform
W54. Targeted eligibility review can decrease the number of inappropriate participants enrolled in clinical trials
W55. IMPACT-EXT: Evaluating the durability and redosing of TSND-201 (methylone) for the treatment of PTSD
W56. Safety, pharmacokinetics, and pharmacodynamics of MSD-001 after single dosing in healthy adults: A randomized, double-blind, placebo-controlled study
W57. Blinding integrity in psychedelic randomized controlled trials: A systematic review
W58. Unlocking medicines for neuropsychiatry by enhancing oral absorption using a lymphatic-targeting prodrug technology
W59. A randomized, placebo-controlled trial of the fatty acid amide hydrolase inhibitor palmitoylethanolamide in bipolar depression
W60. Efficacy, safety and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review
(CRD420251063539).
W61. Beyond mood: Broader psychological benefits of IV ketamine for major depressive disorder
W62. The complex diagnostic profile of psychiatric outpatients presenting for the treatment of bipolar depression
W63. Sodium-glucose cotransporter-2 inhibitors reduce suicidality, all-cause mortality, and hospitalization in bipolar disorder: A cohort study of 1.23 million adults
W64. Preclinical efficacy of concomitant administration of novel GSK3β inhibitor 4MT-A and lithium orotate
W65. The neurobiological effects of psilocybin in treatment resistant bipolar depression: Protocol and interim analysis of clinical outcomes
W66. Effect of cariprazine treatment on sleep and mood symptoms in patients with bipolar I depression and baseline sleep disturbance: Post hoc analysis of three randomized placebo-controlled clinical trials
W67. An open-label, two-arm study of ketamine’s effects on fluid cognition in mood disorders with and without psychosis
W68. Tirzepatide precipitating acute lithium toxicity in stable bipolar I disorder
W69. Effects of cariprazine on symptoms of anxiety: A pooled post hoc analysis of double-blind clinical trials in patients with depression
W70. Real-world impact on anxiety symptoms of cariprazine as adjunctive treatment in major depressive disorder or monotherapy in bipolar I disorder
W71. Antipsychotic switching among patients with bipolar I depression after initiating cariprazine vs lumateperone: A real-world claims-based study
W72. Comparative efficacy of bupropion vs selective serotonin reuptake inhibitors in antidepressant-naive, obese patients with major depressive disorder
W73. Effect of psychedelic therapies on sleep in psychiatric disorders: A systematic review and meta-analysis of randomized clinical trials
W74. Impact of seltorexant on cognitive performance of adults with major depressive disorder with insomnia symptoms
W75. Intermittent white light at 60 Hz as a potential neurostimulation approach for depression: Effects on EEG activity and safety in healthy human volunteers
NCT07111390). W76. safety and efficacy of full and half-dose neuronavigated accelerated theta burst TMS in treatment-naïve adolescent depression
W77. Real-world evidence from legal psilocybin-assisted services in Oregon: Psychedelic preparedness and experiential predictors of mental health outcomes
W78. Protocol for real world safety and effectiveness study of psilocybin therapy
W79. Real-world experience and impact of fatigue in narcolepsy and idiopathic hypersomnia from the ASPIRE survey study
W80. Activation of σ1R and 5-HT2A pathways modulates neuroinflammation, glial repair programs, and BBB responses in demyelinating CNS models
W81. Examining the impact of trauma on ketamine's efficacy in bipolar I/II depression: A secondary analysis from a randomized, midazolam-controlled trial
W82. Real-world persistence on olanzapine/samidorphan versus other oral second-generation antipsychotics in patients with schizophrenia
W83. Using artificial intelligence/machine learning and real-world data to identify patients with schizophrenia for whom an aripiprazole monohydrate LAI is likely to be a favorable treatment option
W84. Endocrine biomarkers of suicide risk in schizophrenia
W85. Clozapine's antagonism is robust against known DRD2 mutations
W86. Impact of negative symptoms on healthcare resource utilization and costs in schizophrenia: A real-world data analysis
95% CI: 0.99-1.39; P=0.06).
W87. Onset, duration, and incidence of adverse events by dose and titration schedule of xanomeline and trospium chloride
W88. SUVN-L1101142, a muscarinic M4 positive allosteric modulator (M4 PAM) for the treatment of psychosis-related disorders and condition
W89. Occurrence of urinary retention-related adverse events with xanomeline and trospium chloride: Results from the 52-week, open-label EMERGENT-5 trial
W90. Olanzapine and samidorphan in adults with schizophrenia or bipolar I disorder: Updated review of clinical data
W91. Longitudinal trends in antipsychotic polytherapy and associated outcomes in schizophrenia
W92. Efficacy and safety of xanomeline and trospium chloride for mania in bipolar disorder: Design of the BALSAM-1 and BALSAM-2 trials
W93. Real-world impact of olanzapine and samidorphan on rates of relapse among young adults with schizophrenia or bipolar I disorder
W94. Translational evidence for dopaminergic alteration of basal ganglia functional connectivity in persons with schizophrenia
W95. Memantine for the treatment of primary negative symptoms in schizophrenia: A meta-analysis of randomized controlled trials
W97. Risk of suicide attempt in newly diagnosed ADHD with and without stimulant treatment within three months of diagnosis
W98. Novel oral rapid-acting neuroactive steroid for treatment of postpartum depression: A placebo-controlled phase 3 clinical trial of lpcn 1154a
W99. Acute treatment of postpartum psychosis: An update from the Massachusetts general hospital postpartum psychosis project
W100. RE104: A novel serotonergic psychedelic 4-OH-DIPT prodrug for the treatment of postpartum depression
W101. Use of long-acting injectable antipsychotics in forensic psychiatry: A multi-site Canadian study
W102. Suicide risk of third-generation antipsychotics in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis
W103. Aripiprazole once-monthly for patients living with schizophrenia: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
W105. Machine learning detection of arousals from at-home sleep EEG device demonstrates comparable performance to expert raters in sleep disorders with and without antidepressant use
W106. Higher polygenic risk for mitochondrial dysfunction is associated with lower cerebral blood flow in youth with bipolar disorder
W107. Choroid plexus volume as a biomarker of ketamine-related improvement in irritability in adults with major depressive disorder
W108. Challenges and strategies for training and retaining the next generation of physician scientists in psychiatry during residency and fellowship
W109. Applying scientific and operational insights from prior clinical trials to optimize efficacy signal detection in a proof of concept trial with KYN-5356 in cognitive impairment associated with schizophrenia
W110. Initial psychometric properties of the anhedonia interview rating scale clinician (AIRS) and self-report (AIRS-SR) among potential psychiatry study participants
W111. A first-in-human study to evaluate safety, pharmacokinetics and pharmacodynamics of KYN-5356, a first-in-class inhibitor of kynurenine aminotransferase II (KAT-II)
W112. Demographic and clinical characteristics of participants receiving COMP360 psilocybin treatment for treatment-resistant depression across two pivotal phase 3 trials
W113. Closing the care gap: Embedding PTSD screening in primary care workflows
W114. Durability of efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) across 26 weeks in a double-blind, randomized, controlled phase 3 study
W115. Elunetirom, a first-in-class, brain-targeting, antidepressant candidate in Ph2 development, triggers robust bioenergetic and neuroplastic improvements in preclinical studies
W116. Lysergide tartrate (LSD; DT120) safety profile from phase 1 and phase 2 clinical studies
W117. Rational deprescribing: ASCP expert consensus for mood disorders
W118. The association between ketamine and esketamine and urological symptoms: Reports to the food and drug administration adverse event reporting system (FAERS)
W119. Efficacy and safety of xanomeline/trospium chloride during transition from atypical antipsychotics in participants with stable schizophrenia symptoms in EMERGENT-5
W120. Silence is golden: Speech production during psilocybin administration sessions for the treatment of post-traumatic stress disorder
W121. A novel interactive digital learning tool (Discover TD®) for psychiatry resident training on diagnosis and treatment of drug-induced movement disorders
W122. Impact of a three-part online educational webinar series on psychiatrists’ knowledge, competence, and confidence in diagnosing and managing tardive dyskinesia
W123. Identifying and predicting symptom trajectories in a blended hybrid digital mental health clinic
W124. Cognitive impairment in major depressive disorder: A patient-prioritized target for functional recovery
W125. Evaluation of VEDAI across clinical psychiatry: A blinded psychiatrist-rated study
W126. Pharmacological validation of neurokit as a portable, sensitive and reproducible test battery in early clinical central nervous system (CNS) drug development
W127. Modeling continuous-time network dynamics of passive sensing and ecological momentary assessment data to characterize treatment response in digital mental health care
T1. Ketamine treatment for non-motor symptoms of Parkinson's disease
T2. Effects of itraconazole and carbamazepine on the pharmacokinetics of remlifanserin (ACP-204) in healthy adults
T3. Correlation of plasma p-tau217 and CSF p-tau181 with clinical diagnosis of Alzheimer’s disease: A cross-sectional study of 1,766 participants in the Alzheimer’s disease neuroimaging initiative
T4. Assessing community pharmacist preparedness to implement methadone dispensing and observation
T5. Understanding kratom’s effects and abuse potential: Design of the first FDA-funded human study
T6. Menstrual phase-driven frontal white matter microstructural dynamics track progesterone and craving variability in women with substance use disorders
T7. Semaglutide for the treatment of opioid use disorder: Interim analysis of a pilot randomized controlled trial
T8. Office-based treatment retention among patients with opioid use disorder and recent fentanyl use: Extended-release injectable buprenorphine vs sublingual buprenorphine
T9. Real-world utilization trends of weekly and monthly injectable buprenorphine (CAM2038) in the United states during the era of high potency synthetic opioids
T10. The pharmacokinetic properties and target engagement effects of the novel serotonin transporter modulator, SNTX-2643, in healthy adults
T11. Efficacy and safety of ulotaront in adults with generalized anxiety disorder: Results from a phase 2/3 randomized placebo-controlled trial
T12. Mazindol IR/SR: A 50-year legacy repositioned as a first-in-class orexin–monoamine modulator for ADHD and arousal-related disorders
T13. Comprehensive multitarget strategy for type 1 diabetes and associated neurological/sleep disorders (DANS): Integrating stem-cell-derived islet replacement, immune modulation, and neuro-circadian therapeutics
T14. Investigating the safety, efficacy, and tolerability of adjunctive cariprazine treatment to psychostimulants in adults with ADHD: A preliminary study
T15. ASRS outcomes across core and expanded symptom domains after 6 weeks of centanafadine treatment in adults with ADHD: A pooled post hoc analysis of two phase 3 trials
T16. Executive function symptom outcomes in adults with ADHD treated with centanafadine: A pooled post hoc analysis of two phase 3 trials
T17. Pathophysiological analysis of autism spectrum disorder focusing on peripheral blood macrophages
T18. Psychotropic prescribing trends within the Texas juvenile justice department from 2016 to 2024
T19. Sleep architecture in participants with insomnia disorder characterized by phenotype: Objective short sleep or objective normal sleep
T20. Psilocybin-assisted psychotherapy for cluster b personality disorders and comorbid treatment-resistant depression
T21. Pharmacotherapies for co-occurring stimulant use disorder and ADHD: A network meta-analysis
T22. Effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs/GLP-1s) integration in patients utilizing antipsychotics
T23. Prevalence of psychotropic medication use among patients with chronic and immune-mediated diseases: A real-world analysis using Epic Cosmos
T24. Prospective replication of an EEG biomarker for predicting changes in attention in ALTO-203, an H3 inverse agonist
T25. BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program
T26. A phase 2 clinical trial exploring efficacy and safety of the vasopressin V1b antagonist BH-200, a treatment for MDD, evaluating the performance of a genetic classification tool to identify a subset of patients with larger improvement
T27. Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder
T28. Effect of ketamine on individual symptoms of depression in a randomized controlled trial of ketamine for treatment-resistant depression
T29. Effects of solriamfetol on neuropsychological outcomes in patients with obstructive sleep apnea in the real-world surwey study
T30. Metabolic profiles of participants with major depressive disorder with insomnia symptoms in a phase 3 trial of seltorexant versus quetiapine extended release as adjunctive therapy
T31. Decrease in negative mood and increase in positive mood during 12 months of vagal nerve stimulation
T32. Use of a prospective lead-in study to enhance eligibility and reduce screen failure in major depressive disorder trials
T33. Metabolic burden, inflammation, and esketamine efficacy in treatment-resistant major depressive episodes
T34. Real-world clinical outcomes of patients switching to treatment with dextromethorphan-bupropion (45 MG/105 mg)
T35. Efficacy and safety of esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: Findings from two early-terminated phase 3 trials
T36. Lumateperone versus other adjunctive atypical antipsychotics for major depressive disorder: A network meta-analysis of comparative efficacy and safety
T37. A phase Ib study evaluating safety, preliminary efficacy, and putative biomarkers of neuroplasticity for the novel neuroplastogen zalsupindole (DLX-001) in major depressive disorder
T38. Real-world effectiveness of intravenous ketamine on depressive symptoms, suicidal ideation and functional impairment in adults with mood disorders
T39. Evaluating the association between antidepressant efficacy and dissociation with ketamine in treatment-resistant bipolar depression (TRBD)
T40. Adjunctive lumateperone 42 mg treatment in major depressive disorder: Efficacy across patient-reported depression symptoms
T41. First onset and duration of treatment-emergent adverse events in patients with major depressive disorder treated with adjunctive lumateperone 42 mg: A pooled analysis of 2 randomized placebo-controlled trials
T42. Remission with lumateperone 42 mg adjunctive to antidepressant therapy in patients with major depressive disorder: Analysis of short-term and long-term trials
T43. Peripheral biomarker reliability in major depressive disorder: A meta-analysis of S100B
T44. Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review
T45. Patterns of real-world antipsychotic switching after initiating adjunctive cariprazine or lumateperone in adults with major depressive disorder
T46. Costs associated with adjunctive atypical antipsychotic– related weight gain among patients with major depressive disorder: An economic model using numbers needed to harm
T47. Preclinical evaluation of ropanicant, a nicotinic acetylcholine α4β2 receptor antagonist in animal models of depression
T48. Ropanicant (SUVN-911), an α4β2 nAChR antagonist: A phase 2b, randomized, double-blind, placebo-controlled, parallel-group study, evaluating the efficacy and safety of ropanicant in patients with major depressive disorder (MDD)
T49. Concurrent oral antidepressant use and clinical outcomes from intravenous ketamine or intranasal esketamine in a real-world sample
T50. Psilocybin treatment for chronic neuropathic pain and depression
T51. Convergent validity and treatment responsiveness of the patient-rated depression checklist (PRDC)
T52. An investigation of the putative antidepressant mechanisms of ketamine, Reelin, and mu opioid receptor agonists in rats and ipsc-derived cerebral organoids exposed to chronic stress
T53. A language-derived affective sentiment dimension of ketamine response in depression
T54. Interpreting psychiatric digital phenotyping data with large language models: A preliminary analysis
T55. A simulation-based framework for characterizing risk in clinically-deployed large language models
T56. AI-enabled patient-derived neuronal models for mechanism-guided antidepressant selection in major depressive disorder
T57. Sustained pharmacodynamic effects of esketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trial
T58. ALTO-207, a fixed-dose combination of pramipexole and ondansetron, suggests efficacy in treating major depression: Findings from a randomized, double-blind phase 2a trial
T59. Effects of alixorexton on patient-reported disease severity, cognitive functioning, and fatigue in patients with narcolepsy type 1: Results from the phase 2 VIBRANCE-1 study
T60. Safety and efficacy results from the phase 2 VIBRANCE-1 study of the orexin 2 receptor agonist alixorexton in patients with narcolepsy type 1
T61. The use of magnetoencephalography (MEG) in a first-in-human trial to demonstrate the functional consequences of target engagement by DT-101, a novel AMPA receptor positive allosteric modulator
T62. Cross trial identification of a predictive enrichment subgroup for esmethadone (rel 1017) in major depressive disorder using explainable machine learning
T63. Prediction of human pharmacokinetic profiles of Glyph platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
T64. Evaluating potential abuse-related adverse events in clinical studies of psychedelics and novel central nervous system active drugs to inform labeling and scheduling recommendations: Issues, methods, and recommendations
T65. DT-101 – a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator demonstrates favorable tolerability and functional biomarkers in phase 1 healthy volunteer trial
T66. Using artificial intelligence/machine learning and real-world data to identify patients with early stage bipolar-I disorder for whom an aripiprazole monohydrate LAI is likely to be a favorable treatment option
T67. Do non-DSM criteria enhance the validity of the DSM-5 mixed features specifier in depressed patients?
T68. Multifocal negative affect: The prevalence and clinical profile of psychiatric outpatients who are depressed, anxious and irritable
T69. The McIntyre and Rosenblat rapid response scale (MARRRS): A psychometric evaluation of patients with treatment-resistant bipolar depression
T70. Changes in sleep patterns with psilocybin-assisted psychotherapy: An exploratory analysis of a randomized clinical trial for treatment-resistant depression
T71. Psilocybin for anhedonia: A systematic review of clinical and preclinical evidence
T72. Don’t let AI make you moody: Assessing racial bias in large language models’ clinical decision-making in mood disorders
T73. Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review
T74. Cognitive outcomes following serial ketamine infusions in treatment-resistant bipolar I/II depression: Results from a randomized, midazolam-controlled trial
T75. A pilot study of sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in major depressive disorder
T76. Efficacy of cariprazine for anhedonia symptoms: A pooled analysis of patients with major depressive disorder and bipolar I depression
T77. Differential effects of transcranial photobiomodulation on functional network reorganization across clinical populations
T78. Comparison of the efficacy of neuromodulation therapies in schizophrenia: A systematic review and network meta-analysis
T79. Harmonizing adverse event criteria to improve CNS-related safety and abuse signal detection in clinical trials
T80. Real-world experience and impact of cognitive impairment in narcolepsy and idiopathic hypersomnia from the ASPIRE survey study
T81. A head-to-head assessment of VMAT2 target occupancy of once-daily valbenazine compared to deutetrabenazine extended release
T82. Opioid use in patients with fibromyalgia: A retrospective claims analysis
T83. Complications of an abrupt switch from a full antagonist to a partial D2 agonist
T84. IMPACT-2: A phase 2 randomized, dose-response trial of TSND-201 (methylone) for the treatment of PTSD
T85. Symptoms of post-traumatic stress disorder in individuals with moderate-to-severe methamphetamine use disorder and changes with tirzepatide treatment
T86. A systematic literature review on anti-psychotic utilization in minority populations and key clinical considerations
T87. DT120 (lysergide, LSD): Assessing the potential risk of cardiac valvulopathy after chronic dosing in rats
T88. Real-world treatment patterns in manic/mixed bipolar I disorder: A US retrospective cohort study
T89. ML-007C-MA, a novel investigational M1/M4 muscarinic agonist in phase 2 development for the treatment of schizophrenia and Alzheimer’s disease psychosis
T90. Efficacy of xanomeline and trospium chloride across symptom domains in adults with schizophrenia: Results from the 52-week, open-label EMERGENT-5 clinical trial
T91. The metabolic-cognitive pathway in schizophrenia: Examining fasting glucose, lipids, and blood pressure as predictors of cognitive impairment and dementia risk
T92. Inpatient initiation of the long-acting injectable antipsychotic aripiprazole lauroxil for the treatment of acute exacerbations of schizophrenia
T93. Safety and efficacy of aripiprazole lauroxil in an outpatient setting after initiation during hospitalization for an acute exacerbation of schizophrenia
T94. LB-102 for acute schizophrenia in adults: Results from the phase 2 NOVA1 clinical trial, focused on PANSS total score responder and CGI-S remitter rates
T95. Role of GLP-1 receptor agonists in managing antipsychotic-related metabolic dysfunction and weight gain
T96. Real-world use of xanomeline and trospium chloride in schizophrenia: Patient characteristics, treatment patterns, and outcomes
T97. Real-world comparison of olanzapine/samidorphan vs olanzapine: An assessment of treatment patterns and acute care events among patients with schizophrenia or bipolar I disorder
T98. Real-world outcomes and psychological predictors in an 8-week hybrid digital clinic for depression and anxiety
T99. Resting-state EEG signatures of suicidal ideation severity and intensity in treatment-resistant depression: Preliminary baseline data from two ongoing clinical trials
T100. Attitudes toward artificial intelligence clinical decision support in psychiatry training: Current evidence and future directions
T101. The national pregnancy registry for psychiatric medications: Risk of major malformations following fetal exposure to second generation antipsychotics
T102. Pregnancy outcomes after first-trimester exposure to vortioxetine: Prospective outcomes from the MGH national pregnancy registry for psychiatric medications
T103. Risk of major malformations following first trimester exposure to cariprazine: Preliminary data from the MGH national pregnancy registry for psychiatric medications
T104. Artificial intelligence–assisted participant recruitment for psychiatric clinical trials: A comparative evaluation of lead quality and engagement
T105. Active and passive digital phenotyping to measure outcomes in a 12-month study of xanomeline/ trospium chloride in schizophrenia: Longitudinal prediction of total changes with early levels of physical activity
T106. Exosomes and a novel mitochondrial mechanism of epigenetic regulation of brain plasticity in treatment resistant depression
T107. Perspectives of nurse practitioners and physician associates on presenting long-acting injectables to adults with schizophrenia: A Delphi panel study
T108. A novel, brain penetrant KAT-II inhibitor, KYN-5356, reduces brain kynurenic acid levels and enhances glutamatergic and cholinergic transmission
T109. Racial differences in antidepressant initiation and outcomes after a one-time psychiatric consultation: A mixed-methods study
T110. Efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) in two phase 3 double-blind randomized controlled studies
T111. Esketamine nasal spray for relapse prevention in patients with treatment-resistant depression: A post hoc analysis of predictors of relapse in placebo-treated patients in SUSTAIN-1
T112. Validation of the neurokit platform for central nervous system pharmacodynamic assessment in healthy volunteers
T113. Connectedness as a mechanism of change in psilocybin-assisted cognitive behavioral therapy
T114. Next-generation pharmacotherapies for mood and anxiety disorders: A comprehensive review of phase II/III drug development across diverse mechanisms
T115. Open-label, randomized study to assess safety and efficacy of slow and accelerated switching to xanomeline/trospium from standard of care atypical antipsychotics in participants with schizophrenia
T116. From nightmares to depression: Age-stratified neuropsychiatric effects of montelukast
T117. Improvement of predominant negative symptoms in patients with schizophrenia on paliperidone palmitate 6-month long-acting injectable: Post-hoc analysis over 3 years
T118. Efficacy of sublingual dexmedetomidine in the home setting for reduction in agitation across baseline severity of symptoms in patients with schizophrenia or bipolar disorder
T119. Long-term metabolic and cardiovascular safety and tolerability with xanomeline and trospium chloride: Pooled results from EMERGENT-4 and EMERGENT-5
T120. Schizophrenia-related hospitalization history before long-acting injectable antipsychotic initiation and its association with subsequent adherence and hospitalizations among dual-eligibles: The critical period study
T121. Outcomes in depression symptomatology with high and low levels of suicidal ideation
T122. Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: A post-hoc analysis of a post-marketing surveillance study
T123. Real-world evidence of clinical treatment response following intravenous racemic ketamine versus intranasal esketamine in adults with major depressive disorder
T124. Multiclass environmental toxicants found in cerebrospinal fluid (CSF) and plasma samples from pregnant women: Potential associations with postpartum depressive symptoms
T125. Continuous multimodal passive monitoring of depressive symptoms via smartphone: Clinical validation of a novel digital health technology
T126. Comparable symptom improvement with electroconvulsive therapy and esketamine in transgender and gender non-conforming adults with treatment-resistant depression
ASCP Annual Meeting 2026 — Abstracts
No abstracts match your search.